Clinical trial
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced…
NCT00362440 · Beth Israel Deaconess Medical Center, Other · Completed
Key facts
| NCT number | NCT00362440 |
|---|---|
| Title | Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome |
| Official title | A Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical Trial |
| Lead sponsor | Beth Israel Deaconess Medical Center, Other |
| Collaborators | American Diabetes Association |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Lipodystrophy |
| Intervention type | Drug |
| Interventions | Leptin, Pioglitazone or metformin, Placebo |
| Enrollment | 9 |
| Start date | Aug 1, 2006 |
| Primary completion | May 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Aug 10, 2006 |
| Last update posted | Mar 23, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: